| Dr Kevin Lamont Collins, DO | |
|
19 Woodland Street, Suite 42, Hartford, CT 06105 | |
| (860) 249-9336 | |
| (860) 247-6897 |
| Full Name | Dr Kevin Lamont Collins |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 19 Woodland Street, Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851362180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QA0505X | Family Medicine - Adult Medicine | 041836 (Connecticut) | Primary |
| 207Q00000X | Family Medicine | 041836 (Connecticut) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Physicians Pc | 1355246950 | 236 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.
They say knowledge is power, and a new UCLA study has shown this is definitely the case when it comes to men making the best decisions about how to treat their prostate cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
A large study jointly led by Queen Mary University of London and UCL aims to identify people at risk of developing Parkinson's, years before the condition is currently detected, with a view to treating and alleviating it at a much earlier stage.
› Verified 6 days ago
| Entity Name | Prohealth Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.
They say knowledge is power, and a new UCLA study has shown this is definitely the case when it comes to men making the best decisions about how to treat their prostate cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
A large study jointly led by Queen Mary University of London and UCL aims to identify people at risk of developing Parkinson's, years before the condition is currently detected, with a view to treating and alleviating it at a much earlier stage.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kevin Lamont Collins, DO 4 Farm Springs Rd, Prohealth Physicians, Farmington, CT 06032-2573 Ph: (860) 284-5200 | Dr Kevin Lamont Collins, DO 19 Woodland Street, Suite 42, Hartford, CT 06105 Ph: (860) 249-9336 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.
They say knowledge is power, and a new UCLA study has shown this is definitely the case when it comes to men making the best decisions about how to treat their prostate cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.
A large study jointly led by Queen Mary University of London and UCL aims to identify people at risk of developing Parkinson's, years before the condition is currently detected, with a view to treating and alleviating it at a much earlier stage.
› Verified 6 days ago
Nicole Poole, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Woodland St, Hartford, CT 06105 Phone: 860-714-7527 | |
Robin B. Gold, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Woodland St, Asylum Hill Family Medicine Center, Inc, Hartford, CT 06105 Phone: 860-714-4212 Fax: 860-714-8080 | |
Joshua M Jones, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 43 Woodland St, Hartford, CT 06105 Phone: 888-793-3500 | |
Robert A Cushman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Woodland St, Hartford, CT 06105 Phone: 860-714-4212 Fax: 860-714-8080 | |
Dr. Marcos Alfonso Iglesias, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Tower Sq # Ms 07, Hartford, CT 06183 Phone: 860-461-8733 | |
Dr. Christine Judith Warner-morin, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St Bldg 502, Hartford, CT 06102 Phone: 860-972-9033 Fax: 860-972-7040 | |
Mohammad Samer Younes, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 99 Woodland Street, Hartford, CT 06105 Phone: 860-714-7527 |